CHARLOTTESVILLE, Virginia, February 11, 2011 — Biovista announced today that it is presenting at the 5th World Generic Medicines Congress, London UK, on Thursday 24 February 2011.
Biovista’s CEO, Dr. Andreas Persidis, will give a presentation on the business and science of repositioning generic medicines at the 5th annual World Generic Medicines Congress Europe of which it is a proud sponsor. This is one of the prime industry events of the year with expert industry speakers and high quality content that discusses developments and opportunities in the generic pharmaceuticals industry.
Dr. Persidis’ presentation will discuss how repositioning generics can lead to new product opportunities and allows the capture of new markets. Biovista’s COSS technology platform that captures the Mechanism of Action (MoA) of compounds and matches this against the MoA of more than 23000 known indications tracked by biomedical research will be presented in detail. Dr. Persidis will present specific examples of Biovista-repositioned generics in multiple sclerosis and epilepsy and discuss the advantages of prolific IP generation in this competitive field.